HL,   FL,  DLBCL,  MCL

Dr. Miguel-Angel Perales | EBMT 2018 | Immune check-point inhibitors in the context of SCT

L: English
Watch Spanish version

  • Dr Perales explains that there have been good results with using checkpoint inhibitors in transplant in Hodgkin lymphoma.
  • He describes a recent German group study comparing the use of upfront checkpoint inhibitors with or without chemotherapy.
  • There can be complications with GvHD in allogeneic transplant and Dr Perales describes a study where transplant was safe with no increased risk of GvHD. 
44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, Portugal
Dr. Miguel-Angel Perales
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF